N4 Group: Profitable Growth at an IPO Premium
The newly listed fitness and sports-nutrition group offers cash-generative growth, but its share sale was mainly an exit for existing shareholders · Serrari IPO Watch · Research cut-off 9 November 2026
N4 Group listed on Euronext Growth Paris under ALN4 on 26 October 2026 at EUR 23.81 a share. The EUR 33.1m aggregate offer was ~79% secondary selling (only EUR 7.0m new capital); FY26 revenue reached EUR 91.1m with EUR 15.3m EBIT — a 24.2x trailing earnings multiple that growth quality must justify.
N4 Group: Profitable Growth at an IPO Premium
SERRARI GROUP / ANALYST DESK — EURONEXT GROWTH PARIS / COMPLETED IPO
The newly listed fitness and sports-nutrition group offers cash-generative growth, but its share sale was mainly an exit for existing shareholders.
EUR 23.81 — IPO admission price on 26 October
EUR 33.1m — Aggregate offer value
EUR 91.1m — FY26 revenue to 31 March
SERRARI IPO RESEARCH SERIES | RESEARCH CUT-OFF: 09 NOVEMBER 2026
RESEARCH & MARKET EDUCATION • NOT A SECURITIES OFFER OR PERSONAL ADVICE
Executive take: not a green-tech float
N4 Group is a consumer wellness and fitness business, already admitted to trading.
Listing status
N4 Group listed on Euronext Growth Paris under ALN4 on 26 October 2026 at EUR 23.81 a share.
Business reality
The company designs and distributes sports nutrition and fitness equipment through 14 brands, e-commerce and a 115-store FitnessBoutique network.
Financial base
FY26 revenue was EUR 91.1m, EBIT EUR 15.3m and net income EUR 11.0m, with a positive operating cash flow profile.
Central question
Can 31% annual sales growth and a 17% EBIT margin be sustained while execution broadens across Europe and post-IPO liquidity remains thin?
Offer structure: primary versus secondary capital
The EUR 33.1m headline is not the same as money raised for corporate investment.
Transaction size
About 1,389,830 offered shares at EUR 23.81 produced EUR 33.1m in aggregate gross sale value.
New issue
Only 293,994 were new shares, representing about EUR 7.0m gross primary capital.
Existing holders
Approximately 1,095,836 existing shares were sold, or about EUR 26.1m of secondary liquidity.
Why it matters
Roughly 79% of the offer value related to secondary shares; investor demand supported shareholder liquidity more than operating funding.
Operating engine: brands plus omnichannel reach
The value chain joins owned product development to several consumer channels.
Nutrition and wellness
Products across fitness, health and performance nutrition generate repeat purchase potential, subject to competition and ingredient costs.
Fitness equipment
Cardio and strength products broaden reach but introduce inventory exposure, fulfilment costs and discretionary-spending sensitivity.
Distribution system
E-commerce, FitnessBoutique outlets, pharmacies and mass retail reduce dependence on any single go-to-market route.
Industrial platform
N4 Labs handles formulation, R&D and production; manufacturing integration can improve quality control but adds operating fixed costs.
FY25 versus FY26: growth was profitable
Full years end 31 March; figures in EUR millions from issuer disclosures.
Metric comparison (periods labeled)
FY25 revenue: 69.47m EUR · FY26 revenue: 91.12m EUR · FY25 operating income: 7.80m EUR · FY26 EBIT: 15.28m EUR · FY25 net income: 5.36m EUR · FY26 net income: 11.03m EUR
Growth bridge
Revenue rose about 31% and reported operating profit almost doubled year-on-year.
Financial period
FY26 ends 31 March 2026; do not treat these figures as calendar 2026 forecasts.
Cash generation: stronger than reported growth alone
The company was profitable and generated cash prior to admission.
Operating cash flow
FY26 net operating cash inflow was EUR 12.28m, compared with EUR 0.79m in FY25.
Free cash flow
The company highlights FY26 FCF of EUR 10.5m and cash conversion of 66% of EBITDA, on its definition.
Net liquidity
As of March 2026, cash and investments of about EUR 16.26m exceeded financial debt of about EUR 11.38m.
What can change
Expansion requires inventory, distribution and marketing investment. Working-capital swings may be more important than reported EBIT margin.
Valuation: a real multiple to defend
IPO capitalisation and historical results provide a simple starting point, not a fair-value conclusion.
Post-IPO equity value
At EUR 23.81 and 11,213,775 issued shares, the implied equity market value was about EUR 267m.
Earnings multiple
IPO equity value / FY26 EUR 11.03m net income is about 24.2x trailing earnings.
Revenue multiple
IPO equity value / FY26 EUR 91.12m revenue is about 2.93x historical sales.
Interpretation
Valuation presumes sustained growth and profitability. Post-IPO float, governance and share liquidity can alter the discount investors require.
Share-price test: early repricing
The 6 November 2026 quote is delayed; no live trading-day estimate is inferred.
Illustrative sensitivity / market values
IPO issue price: 23.81 EUR · 6 Nov close: 23.17 EUR
Indicative return
EUR 23.17 versus EUR 23.81 is roughly −2.7% through 6 Nov, before costs; not a forecast.
Trading volume
Nov 6 reported 1,057 shares traded, highlighting liquidity considerations.
Management targets: ambition versus execution
Targets are issuer aspirations, not contracted revenue.
FY27 revenue
Management targets annual sales above EUR 100m with 20% EBIT margin.
FY29 revenue
Target above EUR 150m and 25% EBIT margin, including roughly 10% international revenue.
Margin bridge
Achieving a 25% margin would require scale benefits to outpace new-store, marketing, production and distribution expense.
Analyst test
Assess international economics and repeat-customer retention before underwriting a steady uplift in operating profit.
Capital flows: why deal design matters
A mostly secondary IPO creates different growth financing than a large new-share issuance.
Growth capital
EUR 7.0m of new gross equity supports the company before fees; this is much smaller than total headline proceeds.
Shareholder liquidity
Secondary selling transfers existing stakes to public investors without providing fresh corporate cash.
Free float and turnover
Small-cap liquidity can be thin; modest trade sizes may move the price more than fundamentals in the first weeks.
Use of funds
Track cash deployed into distribution, industrial capabilities and acquisitions rather than extrapolate from the IPO label.
Risk map: profitable does not mean low-risk
| Risk / exposure | Likelihood | Impact | Investment relevance |
|---|---|---|---|
| Valuation compression | Medium | High | 24x trailing earnings embeds growth expectations. |
| Growth execution | Medium | High | FY27/FY29 targets require international scaling. |
| Discretionary spending | Medium | High | Equipment and supplements depend on consumer demand. |
| Small-cap liquidity | High | Medium | Thin trading can magnify short-term volatility. |
| Inventory and supply | Medium | Medium | Brand expansion can tie up operating cash. |
Likelihood and impact are qualitative judgments.
Figure: Risk map — profitable does not mean low-risk.
Scenario map: valuation paths after admission
The key variable is realised operating margin and growth, not the IPO date.
Profitable expansion
Europe channels scale, operating leverage holds and the company delivers FY27 targets with good cash conversion.
Measured growth
Sales advance, but margins stabilise below management ambitions; valuation converges toward ordinary consumer peers.
Demand slowdown
Discretionary fitness equipment and supplements soften as consumers trade down and promotional intensity rises.
Liquidity discount
Low turnover, governance concerns or secondary selling weigh on share prices despite acceptable operating results.
Monitoring dashboard: six operating checkpoints
Report updates should distinguish issuer guidance from realised numbers.
Revenue mix — Nutrition versus equipment; own channels versus partners.
Gross margin — Ingredient, logistics and promotional costs.
Cash conversion — Working capital and replenishment requirements.
Expansion — International sales and store productivity.
Equity market — Float, trading volume and price formation.
Guidance delivery — FY27 revenue and 20% EBIT target.
Market assessment: what the evidence supports
Financial and listing facts are separated from analyst scenarios.
Serrari view: growth quality must justify the entry multiple
N4 Group entered public markets with real profits, cash generation and an integrated consumer-product platform. Yet only about one-fifth of its offer value provided fresh company capital, while the implied IPO earnings multiple demands sustained expansion. The most informative future evidence will be margins, working capital and international productivity.
24.2x — Trailing FY26 earnings at IPO value
~21% — Gross deal value from new shares
17% — Issuer-reported FY26 EBIT margin, rounded
THE NEXT DECISION POINT
Monitor FY27 results against guidance, operating cash flow, free float and the quality of growth across retail channels.
Sources, methodology and limitations
SERRARI GROUP / ANALYST DESK
Use the linked descriptive phrases below to open the supporting filing, announcement or market record.
N1 — Completed listing, share counts and IPO price
N2 — Exchange issue information and ticker record
N3 — Issuer financial position, strategy and targets
N4 — Issuer FY26 accounts reproduced in listing announcement
N5 — 6 November delayed share price and early trading history
N6 — Issuer FY26 historical cash and debt comparison
METHODOLOGY & COMPARABILITY
Euronext identifies the actual admission date as 26 Oct 2026, superseding earlier indicative issuer timetable. Shares offered total approximately 1,389,830, of which 293,994 were new and 1,095,836 secondary. IPO multiples use €267m offer capitalisation divided by FY March 2026 results, not post-IPO forecast earnings. 6 Nov quote is delayed; financial numbers reflect historical fiscal accounts.
ANALYST INTERPRETATION & CAUTIONS
All opinions and risk ranks are qualitative analyst judgments rather than probability estimates or financial advice. Figures are as of the stated source dates, not a real-time quote service. Offering terms can change. No recommendation to buy, sell or subscribe to any security is made.
Prepared 09 November 2026 | Serrari Group | Research and market education